The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
A pharma industry veteran with over three decades of experience in domestic as well as international markets
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Subscribe To Our Newsletter & Stay Updated
